摘要
为分析嗅神经母细胞瘤(esthesioneuroblastoma ENB)的临床特点,并探讨其预后因素及治疗方法,回顾性分析1995年7月～2006年8月10例经病理确诊的ENB患者,改良Kadish分期示A期1例,B期5例,C期2例,D期2例。单纯手术治疗3例,单纯放射治疗1例,综合治疗6例(手术+放射治疗4例,手术+放射治疗+化疗2例)。全组5年生存率(OS)和5年无瘤生存率(DFS)分别为71.4%和62.5%,KadishA/B期和C/D期的5年OS分别为100.0%和33.3%(χ2=3.28,P=0.07),有颈部淋巴结和无颈部淋巴结转移者的5年DFS分别为0和83.3%(χ2=8.33,P=0.004),综合治疗(≥2种治疗方式)与单纯手术加单纯放疗的5年OS为80.0%和50.0%,5年DFS为80.0%和33.3%(χ2=1.06,P=0.30)。初步研究结果提示,随着诊断技术的提高,ENB的报道较前增多;该病的预后与Kadish分期及颈部淋巴结是否转移相关,治疗上,以包括手术的综合治疗为主,放射治疗在该病的治疗中占有重要地位。
The objective of this study was to analyse the clinical character istic and discuss the prognosis and treatment of esthesioneuroblastoma（ENB）. Ten patients with esthesioneuroblastoma were reviewed retrospectively. According to the modified Kadish＇s staging, there was one of stage A, five of stage B, two of stage C, and two of stage D . Three patients were treated with surgery alone, one with radiotherapy alone, six with combined therapy（including four with surgery and radiotherapy, and two with surgery plus radiotherapy and chemotherapy）. The S-year overall survival （OS） and disease free survival （DFS） were 71.4% and 62.5% respectively. The S-year OS（s） of Kadish＇s stage A/B and C/D were 100% and 33.3%（x^2 =3.28, P=0.07）. The S-year DFS（s） for patients with and without cervical lymph node metastasis were 0 and 83.3 % （x^2= 8.33, P= 0. 004）. The S-year OS（s） for patients treated with combined therapy and with surgery alone plus radiotherapy alone were 80.0% and 50.0%. The S-year DFS （s） of them were 80.0 %, 33.3 % （x^2 = 1.06, P= 0.30）. With the improvement of the diagnosis, the patients with esthesioneuroblastoma increase. The prognosis of esthesioneuroblastoma has a relation with the Kadish＇s staging and lymph node metastasis. The combined treatment including surgery should be the major treatment, and radiotherapy plays an important role in the treatment of the disease.
出处
《中华肿瘤防治杂志》
CAS
2007年第22期1728-1729,共2页
Chinese Journal of Cancer Prevention and Treatment
